We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+5.04%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$6.97B
AUM Growth
-$106M
Cap. Flow
-$271M
Cap. Flow %
-3.88%
Top 10 Hldgs %
34.81%
Holding
187
New
15
Increased
42
Reduced
87
Closed
11

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$28.5M
2
CLDX icon
Celldex Therapeutics
CLDX
+$26.8M
3
EXAS
Exact Sciences
EXAS
+$15.3M
4
TNDM icon
Tandem Diabetes Care
TNDM
+$13.7M
5
CRL icon
Charles River Laboratories
CRL
+$6.89M

Top Sells

Rank Stock Value
1
RDUS
Radius Health, Inc.
RDUS
+$91.2M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$38.7M
3
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$24M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$19.3M
5
AXSM icon
Axsome Therapeutics
AXSM
+$16M

Sector Composition

Rank Sector Weight
1 Healthcare 99.34%
2 Industrials 0.59%
3 Energy 0.02%
4 Communication Services 0.01%
5 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KOS icon
126
Kosmos Energy
KOS
$1.36B
$1.65M 0.02%
318,300
– –
COR icon
127
Cencora
COR
$59.1B
$1.61M 0.02%
11,910
-1,090
-8% -$157K
NPCE icon
128
Neuropace
NPCE
$537M
$1.46M 0.02%
388,368
-119,562
-24% -$576K
AKRO
129
DELISTED
Akero Therapeutics
AKRO
$1.42M 0.02%
+41,634
New +$637K
ZLAB icon
130
Zai Lab
ZLAB
$2.32B
$1.28M 0.02%
+36,600
New +$1.57M
KRYS icon
131
Krystal Biotech
KRYS
$10B
$1.28M 0.02%
18,300
+4,900
+37% +$354K
RGEN icon
132
Repligen
RGEN
$8.21B
$1.24M 0.02%
+6,600
New +$1.39M
CELL
133
DELISTED
PhenomeX Inc. Common Stock
CELL
$1.1M 0.02%
385,014
– –
SEER icon
134
Seer Inc
SEER
$112M
$1.05M 0.02%
136,133
– –
A icon
135
Agilent Technologies
A
$36.8B
$1.05M 0.02%
+8,627
New +$1.11M
MCK icon
136
McKesson
MCK
$97.3B
$999K 0.01%
2,938
+401
+16% +$139K
DNLI icon
137
Denali Therapeutics
DNLI
$3.63B
$951K 0.01%
+31,000
New +$1.01M
VRDN icon
138
Viridian Therapeutics
VRDN
$2.05B
$946K 0.01%
46,100
-2,900
-6% -$52.1K
ONC
139
BeOne Medicines Ltd
ONC
$32.2B
$940K 0.01%
+7,000
New +$1.2M
LH icon
140
Labcorp
LH
$23.1B
$799K 0.01%
4,540
-407
-8% -$83.3K
INBX
141
DELISTED
Inhibrx, Inc. Common Stock
INBX
$781K 0.01%
43,500
-33,100
-43% -$597K
CRBU icon
142
Caribou Biosciences
CRBU
$161M
$699K 0.01%
66,300
-4,000
-6% -$37.3K
RDY icon
143
Dr. Reddy's Laboratories
RDY
$10.4B
$664K 0.01%
62,000
– –
XNCR icon
144
Xencor
XNCR
$1.39B
$660K 0.01%
25,400
-1,100
-4% -$31.5K
SPY icon
145
State Street SPDR S&P 500 ETF Trust
SPY
$781B
$643K 0.01%
+1,800
New +$715K
DSGN icon
146
Design Therapeutics
DSGN
$741M
$583K 0.01%
+34,881
New +$694K
GOOG icon
147
Alphabet (Google) Class C
GOOG
$4.29T
$577K 0.01%
6,000
– –
MRUS
148
DELISTED
Merus
MRUS
$509K 0.01%
+25,400
New +$606K
BMY icon
149
Bristol-Myers Squibb
BMY
$123B
$502K 0.01%
7,062
-17,845
-72% -$1.29M
XOP icon
150
State Street SPDR S&P Oil & Gas Exploration & Production ETF
XOP
$3.34B
$486K 0.01%
+3,900
New +$515K
4 5
6
7 8

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2022 Portfolio in Review

As of Q3 2022, Bellevue Group held 187 positions worth $6.97B, down 1.5% from $7.07B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Bellevue Group withdrew a net $271M in Q3 2022, closing 11 positions and reducing 87 holdings. Its most notable exit was Radius Health, Inc., an estimated $91.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Industrials and Energy.

Against the trend, Bellevue Group opened a new position in Zai Lab worth $1.28M.

  • Bellevue Group's largest Q3 2022 buy was Zai Lab: 36,600 shares worth $1.28M.
  • Bellevue Group added most to Revolution Medicines in Q3 2022, an estimated $28.5M increase.
  • Bellevue Group's biggest Q3 2022 reduction was Sarepta Therapeutics, cutting an estimated $38.7M.
  • Bellevue Group fully exited Radius Health, Inc. in Q3 2022, selling an estimated $91.2M.
  • Bellevue Group's ten largest holdings make up 35% of its $6.97B portfolio in Q3 2022.
  • Bellevue Group opened 15 new positions and closed 11 in Q3 2022.
  • Bellevue Group's portfolio value fell 1.5% quarter-over-quarter to $6.97B.

Based on Bellevue Group's 13F filing for Q3 2022, filed 14 Nov 2022.